Page 2 - Read Online
P. 2
Topic: Recent advances
in Tumor-Targeting
Chemotherapy Drugs
Dr. Iwao Ojima received his BS, MS and PhD (1973)
from the University of Tokyo, Japan. He joined the
faculty in the Department of Chemistry, State University
of New York at Stony Brook (1983), promoted to
University Distinguished Professor (1995). He served
as the Department Chair (1997-2003), and has been
serving as the founding Director for the Institute of
Chemical Biology and Drug Discovery (2004-), as well
as the President of the Stony Brook University Chapter
of the National Academy of Inventors (NAI) (2016-). His
research spans broadly at the interfaces of chemistry,
biology and medicine, including anticancer, antimicrobial
Iwao Ojima and anti-inflammatory agents. His seminal contributions
Department of Chemistry, Stony to the development of paclitaxel and new-generation
Brook University, Stony Brook, taxane anticancer agents, as well as their tumor-targeting
NY, USA. drug conjugates are widely recognized. His awards and
honors include Arthur C. Cope Scholar Award (1994), E.
B. Hershberg Award (2001), Medicinal Chemistry Hall of
Fame (2006), ACS Award for Creative Work in Fluorine
Chemistry (2013) and Ernest Guenther Award (2019)
from the American Chemical Society; Elected Fellows
of J. S. Guggenheim Memorial Foundation, American
Association for the Advancement of Science, The New
York Academy of Sciences, American Chemical Society,
National Academy of Inventors and European Academy
of Sciences.
